Salubris Biotherapeutics is a clinical-stage biotechnology company developing complex biologic therapeutics for cardiovascular, oncology, and neurodegenerative indications. Its lead candidates include JK07, a recombinant IgG1–NRG-1 fusion designed to selectively stimulate HER4/ErbB4 signaling; JK08, a CTLA-4 antibody–IL-15 fusion for solid tumors; and JK06, a preclinical biparatopic antibody-drug conjugate. JK07 completed patient dosing in a Phase 1b HFrEF study with topline results planned for presentation and is slated to begin a Phase 2 study in the second half of 2023 while a Phase 1b HFpEF study is actively enrolling. JK08 is in an ongoing Phase 1/2 study for solid tumors with a fourth cohort now recruiting and preliminary favorable safety and dose-dependent pharmacodynamic activity reported in early cohorts. The company was founded in August 2016 as a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals and is headquartered in Gaithersburg, Maryland. In 2023 it received a $35 million financing from Shenzhen Salubris Pharmaceuticals to advance JK07 into Phase 2, continue JK07 HFpEF and JK08 trials, launch a neurology trial for JK07, and advance JK06 toward initial clinical testing. Salubris Biotherapeutics is a clinical-stage biotech focused on discovering and developing novel complex biologic therapeutics for cardiovascular, oncology, and neurodegenerative diseases. Its lead asset, JK07, is an antibody-based NRG-1 fusion protein in Phase 1 trials for heart failure with reduced ejection fraction (HFrEF) and is the first bi-specific antibody globally to enter a cardiovascular clinical trial. Cohort 1 (n=5) of the randomized, double-blind, placebo-controlled dose-escalation HFrEF study showed a favorable safety profile and signals of clinical benefit, including up to an 18% absolute improvement in ejection fraction. The company says the FDA has agreed to the initiation of a Phase 1 study of JK07 in heart failure with preserved ejection fraction (HFpEF) and that preparations for that trial are underway while Cohort 2 enrollment in HFrEF is ongoing. SalubrisBio has multiple assets across clinical and preclinical development and additional discovery-stage programs. The company announced a $32 million financing from Shenzhen Salubris Pharmaceuticals in Q4 2021 to advance the pipeline, continue the ongoing Phase 1b trial and initiate two additional Phase 1b trials in 2022, and to expand R&D.

Total raised

$67M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2023